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Abstract 
Twenty-five years after the Revised European American Lymphoma (REAL) classification was 
published, its principle of an integrative approach to disease definition based on several parameters still 
prevails and has been adopted and expanded in the following World Health Organization (WHO) 
classifications of tumors of the haematopoietic organs. The latest WHO classification revised in 2017 
comprises more than 80 entities of mature lymphoid neoplasms (B-cell, T-cell and Hodgkin lymphomas) 
which are defined according to their morphology, immunophenotype, genetic lesions and molecular 
profiles, clinical features and cellular derivation. The classification also recognizes both incipient and 
indolent lymphoid neoplasms with a low potential of proegression. In this review we highlight some of 
the new data and recent modifications introduced in the 2017 classification.  
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A historical perspective of lymphoma classification 
 
Few areas in pathology have evoked as much controversy and confusion as the classification of 
lymphoid neoplasms, dating back to the first attempts to organize the variety of described neoplasms 
into a comprehensive scheme. The difficulties resulted from several factors, notably the diversity of 
lymphoid tumors, and the relative insensitivity of routine histopathological techniques that are useful in 
other organ systems in recognizing defining features of lymphoid cells and their tumors. Later on, in 
parallel with advances in immunology and genetics, and with the development of novel technologies, 
the past decades have witnessed major advances in the knowledge of lymphoma pathology, biology and 
genetics, which translated to novel concepts for the classification of lymphoma (Figure 1)1,2. 
Before 1970, several purely morphologically oriented descriptive classifications of lymphomas 
were proposed 3-6. The Rappaport proposal (1966) was the first clinically relevant classification6. 
Broadly speaking, Rappaport divided lymphomas into those composed of small cells and of large cells, 
and further subdivided according to follicular (or nodular) versus diffuse growth patterns. The follicular 
and small-cell tumors were clinically less aggressive; a better survival could therefore be expected and, 
importantly, less potent and less toxic therapy was suitable for these cases. The converse applied to 
cases with a diffuse growth pattern, especially if composed of large cells. 
Immunologic advances in the 1960’s and 1970’s revolutionized the understanding of the 
immune system and lymphomas. The existence of several lymphoid lineages was discovered, and it 
became possible to establish the phenotype of lymphoma cells using monoclonal antibodies and 
immunolabeling techniques. Soon it became evident that the lymphoma cells were closely related to 
normal lymph node cells and that the cells of the non-Hodgkin lymphomas recapitulated the cytology 
of normal lymphocytes, particularly the B cells of the follicle center. Several new schemes based on 
these new concepts appeared. The Kiel Classification7,8 developed by Karl Lennert in Germany became 
widely used in Europe; in this approach primarily intended for classification of nodal diseases, 
lymphomas were classified according to a hypothetical scheme of B- and T-lymphocyte differentiation, 
and the nomenclature reflected the putative normal counterpart of the neoplastic cells. According to 
their cytological characteristics rather than their predetermined clinical behavior and in keeping with 
established schemes for other tumors, the lymphomas were designated low-grade and high-grade. The 
classification developed by Lukes and Collins (1974) in the United States was based on similar 
concepts9, and several other proposals appeared shortly after.  
Because of the multiplicity of classifications causing much confusion, the compromise 
« Working Formulation for Clinical Use » (NHL Classification Project, 1982) was developed and 
designed to « translate » between the various classifications10. In this scheme, non-Hodgkin lymphomas 
were divided on clinical grounds into three prognostic groups: low, intermediate and high-grade. Within 
each group, classification was based purely on morphologic criteria, in particular the nodular versus 
diffuse growth pattern and the size of the tumor cells (small versus large versus mixed small and large). 
As a result, different clinico-pathological entities were lumped together and the Working Formulation 
did not incorporate immunophenotypic data. In the 1980’s and early 1990’s, the Working Formulation 
became the standard American11 classification, while the Kiel classification was most widely used in 
Europe. This lack of consensus on lymphoma classification and terminology caused problems for both 
pathologists and clinicians, and caused difficulty in interpreting published studies. In addition, in the 
1980's and 1990's, many new disease entities were described, for example mantle cell lymphoma12 and 
extranodal marginal zone lymphoma13, which were not included in either classification. At the same 
time there were tremendous advances in the understanding of the genetic basis of B-cell lymphomas 
with the successive discovery of several recurrent translocations and protooncogenes (BCL2, MYC, 
CCND1) 14,15. The progresses made in immunogenetics with the descriptions of the process of gene 
rearrangement of immunoglobulin and T-cell receptor genes in normal lymphocytes, and of somatic 
hypermutations occurring in immunoglobulin genes during transit through the germinal center, were 
soon exploited to infer clonality and lineage derivation of lymphoid neoplasms, and differentiation stage 
of B-cell neoplasms 11,16.  Ultimately, the introduction of the new techniques of immunophenotyping 
and molecular genetic analysis led to confusion about what, if anything, should be the modern "gold 
standard" for defining disease entities. 
In 1991, Peter Isaacson and Harald Stein founded the International Lymphoma Study Group 
(ILSG) to promote a better communication between hematopathologists from Europe and America. The 
group composed of 19 prominent hematopathologists from the United States, Europe and Asia at that 
time, aimed at defining “real” disease entities on which they could reach a consensus based on published 
data.  This approach represented a new paradigm in lymphoma definition and classification.  A 
consensus list of well-defined disease entities was published in 1994 as the REAL (Revised European-
American Classification of Lymphoid Neoplasms) classification1. Some entities were listed as 
provisional due to insufficient knowledge or evidence for establishing them as definitive. In the REAL 
classification, distinct lymphomas defined by a constellation of five properties, namely morphology, 
immunophenotype, genetic features, clinical features, and if possible the normal cell counterpart from 
which they derive. The degree to which these properties contribute to the classification of each disease 
entity is variable. The integration of clinical features into lymphoma definition, which is particularly 
important for T-cell and NK-cell lymphomas, was a very innovative aspect of the REAL classification. 
Later on, the notion that the site of lymphoma presentation could represent a signpost for important 
underlying biologic distinctions was later reflected in the delineation of several “organ-specific” 
lymphoma entities, notably specific extranodal entities of diffuse large B-cell lymphomas (primary 
mediastinal, leg-type, of the central nervous system) or follicular lymphomas (cutaneous, duodenal-
type, testicular). Although the initial publication of the REAL classification elicited considerable 
controversy17, experience over the following years showed that it could be reproducibly applied by most 
pathologists and that the entities described have distinctive clinical features, making it a useful and 
practical classification18,19.  
  Shortly after the publication of the REAL classification, the World Health Organization (WHO) 
commissioned the European and American Societies of Hematopathology, to provide an update of the 
classification of hematopoietic and lymphoid neoplasms for its “blue book” series. In addition to many 
hematopathologists, the joined project which took several years also involved a large clinical advisory 
committee to address questions of clinical relevance.  The principles of disease definition and consensus 
developed in the REAL classification were essentially maintained. The WHO classification of 
lymphomas published at the end of 2001 2 represented the first true international consensus on the 
classification of hematologic malignancies, and gained acceptance worldwide as the reference for 
pathologists, clinicians, scientists and researchers. Significantly, the monograph belonged to a new 
series of blue books entitled “pathology and genetics of cancer” emphasizing the contribution of genetics 
to tumor classification.  Since 2001, the WHO classification of tumors of hematopoietic and lymphoid 
tissues was updated in 200820 and the latter edition was revised in 201721.  While the original principles 
still prevail the successive editions have been expanded to incorporate new knowledge and emphasize 
novel concepts resulting in an increasing number of entities and amount of information. In the last 
edition, the “genetic profile” sections are in general markedly enlarged and comprise a lot of new data 
derived from the many next-generation sequencing studies performed over the past few years, including 
molecular signatures, (epi)genetic profiles, mutational landscapes and new fusion genes, which 
mechanistically may correspond to translocations, intrachromosomal deletions or inversions. The 
genomic landscapes of the most common non-Hodgkin lymphoma entities show wide heterogeneity 
within and across subtypes, but there are also similar altered pathways and mechanisms of oncogenesis 
overlapping across different entities.22. Various genes belonging to multiple functional pathways are 
mutated, and the pattern of mutations for each gene is variable: some genes like BRAF or MYD88 are 
characterized by one or a few hotspot alterations23 ,24, or the mutations may be more heterogeneous. 
Sometimes distinct mutations in the same gene may be either activating or loss-of-function, and 
mutations with apparently discordant functional impact may be encountered in different cases of the 
same disease25.  Some disease entities are associated to a very characteristic mutational profile, involving 
one or a few genes, while other diseases are genetically more heterogeneous 26. 
 
The WHO classification of lymphoid neoplasms 
In the 2017 classification, more than 80 mature lymphoma entities are recognized, grouped into three 
major categories: B-cell neoplasms, T-cell and NK-cell neoplasms, and Hodgkin lymphomas (Table 1).  
Both lymphomas and lymphoid leukemias are included in this classification. The disease entities are 
listed according to predominant clinical presentation (predominantly disseminated diseases that often 
involve bone marrow and may be leukemic, primary extranodal lymphomas, and predominantly nodal 
diseases - which are often disseminated and may also involve extranodal sites -). There is an additional 
section on immunodeficiency-associated lymphoproliferative disorders addressing the spectrum of 
lymphoproliferations and lymphomas associated with primary immune deficiencies, HIV infection, in 
the post-transplant setting or in other iatrogenic conditions.  
Following the principles of lymphoma classification, lymphoma diagnosis is based on the 
appreciation of morphologic and immunophenotypic features, genetic characteristics, in the context of 
clinical presentation. Assignement to a disease category requires the integration of these pieces of data 
for a final interpretation. In practice, morphologic interpretation combined to immunophenotyping 
represent the essential elements and are sufficient to establish the diagnosis in many cases. Technical 
factors in the preparation of the lymph node specimens are of critical importance for obtaining high-
quality conventional histologic preparations, which are the essential starting point for accurate 
diagnosis27. In principle the immunologic or molecular studies should always be interpreted in the light 
of the clinical and histopathogical features. Immunophenotype is an essential defining characteristic of 
lymphomas. In the assessment of malignant lymphoproliferations, immunophenotyping is used (1) to 
determine cell lineage and differentiation stage, (2) to infer clonality from immunoglobulin light chain 
expression in the case of B-cell lymphoproliferations, and (3) to identify markers of specific genetic 
alterations.  Immunoglobulin and T-cell receptor gene rearrangement studies are useful to characterize 
the clonality status of lymphoproliferations, results should again always be interpreted with caution as 
there are many examples of clonal proliferations that may remain subclinical or indolent. Moreover, 
pseudoclonal results may be generated from small biopsies with limited infiltrates and PCR 
amplification of a limited repertoire. Molecular or genetic testing is mandatory to assign a diagnostic 
category in some instances, for example FISH studies searching for MYC, BCL2 or BCL6 gene 
rearrangements are necessary for the categorization of high-grade B-cell neoplasms28. Next generation 
sequencing technology has also entered the diagnostic arena, and can provide complementary 
information to support diagnoses29. 
 
B-cell lymphomas 
Mature B-cell neoplasms comprise over 80% of NHL. The most common types are follicular lymphoma 
and diffuse large B-cell lymphoma, which together account for more than half of all NHL. B-NHL 
entities comprise a range of morphologically, phenotypically, genetically and clinically distinct 
malignancies. The majority of B-NHL harbor somatically mutated IG genes and therefore are derived 
from germinal center (GC) or post-GC B cells. The correspondence to normal B-cell subpopulations 
initially assessed by a combination of morphology and immunophenotype, has been refined by the 
comparison of gene expression signatures of lymphomas and normal B cell subpopulations across the 
full range of normal B-cell differentiation.  Figure 2 illustrates the model of histogenesis and 
pathogenesis of B-cell neoplasms. 
Several entities of B-cell neoplasms represent early or indolent clonal lymphoid lesions. 
Monoclonal B-cell lymphocytosis and monoclonal gammopathy of unknow significance are the 
subclinical precursor lesions to B-chronic lymphocytic leukemia and plasma cell myeloma, respectively 
30. In situ follicular neoplasia (not uncommon) and in situ mantle cell lymphoma (distinctively rare) 
denote tissue accumulation restricted to germinal centers of mantle zones, of B cells harboring the BCL2 
or CCND1 hallmark translocations of follicular or mantle cell lymphoma31. In situ follicular neoplasia 
is considered the tissue equivalent of circulating blood cells harboring the t(14;18) translocation found 
in many healthy individuals; compared to clinically overt follicular lymphoma the load of additional 
genetic alterations is low in in situ follicular neoplasia32, and the risk of progression to clinical disease 
is low33. Duodenal-type follicular-type is somewhat assimilated to in situ follicular neoplasia, because 
this t(14;18)+ neoplasm which arises in the mucosa of the proximal duodenum is often discovered 
incidentally and has an indolent course with a very low risk of local progression or dissemination34. 
Major changes have been introduced in the classification and diagnosis of aggressive B-cell 
lymphomas, which fall into three main categories: diffuse large B-cell lymphomas (DLBCLs), Burkitt 
lymphoma (BL), and two novel entities of high-grade B-cell lymphomas35.  DLBCLs constitutes the 
most prevalent group and comprises many entities unified by a simple definition, i.e. a proliferation of 
large transformed B cells. Specific entities are related to occurrence in peculiar anatomic sites (primary 
mediastinal, primary cutaneous leg-type, primary DLBCL of the central nervous system, intravascular),  
some are classified based on a plasmablastic phenotype (plasmablastic lymphoma and ALK-positive 
DLBCL) or an abundant microenvironment (T-cell/histiocyte-tich large B-cell lymphoma),  others are 
defined by their association to viral infections +/- a peculiar clinical context (EBV+ DLBCL, EBV+ 
muco-cutaneous ulcer, DLBCL with chronic inflammation, lymphomatoid granulomatosis, primary 
effusion lymphoma, HHV8+ DLBCL-NOS). For the usual form of DLBCL (“NOS”) it is recommended 
to identify the two molecular subtypes defined by gene expression profiling, germinal center-like and 
activated B-cell like, because these two subtypes correspond to distinct pathogenetic pathways. In a 
routine setting, this is achieved in most centers by the use of immunohistochemical algorithms or 
simplified RNA profiling methods36-39. Besides Burkitt lymphoma which is a very homogeneous 
category, a new provisional entity named Burkitt-like lymphoma with 11q aberration has been 
introduced, referring to a limited number of cases resembling Burkitt lymphoma, but lacking a MYC 
translocation, having more complex karyotypes and a chromosome 11q aberration40.  The categories of 
high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, and high-grade B-cell 
lymphoma, not otherwise specified, were newly introduced. These new categories partly substitute for 
the former group of “unclassifiable B-cell lymphoma with features intermediate between diffuse large 
B-cell lymphoma and Burkitt lymphoma”, which is no longer recognized. High-grade B-cell lymphomas 
may morphologically resemble DLBCL, have features intermediate between DLBCL and Burkitt 
lymphoma (high proliferation fraction and a starry sky appearance with cells larger or more pleomorphic 
than the spectrum of classical Burkitt lymphoma, or a morphology resembling Burkitt lymphoma with 
a discordant immunophenotype, typically strong BCL2 expression), or have a blastoid morphology. A 
sizeable fraction of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements, 
also simply termed « double hit » or « triple hit » lymphomas, represent transformed follicular 
lymphomas. MYC plus BCL2 double hit lymphomas are usually GCB and those with MYC and BCL6 
rearrangement are usually ABC. High-grade B-cell lymphomas NOS by definition do not have double 
or triple hits, but a significant proportion carries a MYC rearrangement (alone). An important 
consequence of this new classification is that assignement of a large B-cell neoplasm to the DLBCL 
category requires genetic testing at least for MYC +/- BCL2 and BCL6 rearrangements, in order to 
exclude the possibility of a “double hit” lymphoma. 
 
T-cell lymphomas 
Neoplasms of mature NK or T cells (PTCLs) are overall rare. They comprise approximately 10% of all 
lymphomas in Western world, while in Asia where EBV-associated extranodal NK/T-cell lymphoma 
(and adult T-cell leukemia/lymphoma) are more frequent, they represent up to 20% of lymphomas. The 
delineation of mature NK/T-cell neoplasms into entities along the WHO scheme is not as sharp as for 
the B-cell tumors, in regard to the numerous T-cell subsets and their functional plasticity. Indeed many 
T/NK-cell neoplasms have a broad range of cellular composition, and immunophenotypic profiles may 
be heterogeneous within a disease category while overlapping across different entities. Recent advances 
in characterizing the molecular profiles and mutational landscapes of these diseases have translated into 
significant changes in the classification.   
With regard to nodal PTCLs (Figure 3), a major change was the grouping of 
angioimmunoblastic T-cell lymphoma and two related entities, namely follicular T-cell lymphoma and 
nodal T-cell lymphoma with a T follicular helper phenotype, under a common heading named “nodal 
lymphomas derived from follicular helper T cells (TFH cells). The rationale is that these three entities 
have in common not only an immunophenotype and gene expression signature similar to those normal 
TFH cells, but also a similar genetic landscape, characterized by recurrent mutations in epigenetic 
modifier genes (TET2, DNMT3A, IDH2), RHOA and other T-cell receptor signaling genes 41-48. Nodal 
T-cell lymphoma with a T follicular helper phenotype is defined as a PTCL lacking the peculiar 
morphological features characteristic of AITL, but showing expression of several (at least two, optimally 
at least three) TFH markers, and this entitiy includes many cases categorized in the past as “Lennert 
lymphomas” (rich in epithelioid cells) or nodal T-zone lymphomas. Anaplastic large cell lymphoma 
(ALCL), ALK-negative, is now viewed as a genetically heterogeneous entity comprising at least two 
subsets defined by recurrent translocations affecting DUSP22 (about 30% of the cases, and associated 
to a good prognosis similar to that of ALK-positive ALCL) or TP63 (10% of the cases, associated with 
a poor outcome) 49,50. Since DUSP22-rearranged cases may not fulfill all the phenotypic attributes of 
ALK-negative ALCL, their identification is important to clarify the sometimes difficult differential 
diagnosis with CD30-positive PTCL-NOS. In addition, a proportion of ALK- ALCL also carry 
mutations impacting on the JAK/STAT pathway51, a feature also reported in primary cutaneous ALCL51 
and breast implant-associated ALCL 52-54. The latter was introduced as a provisional entity in the 
classification due to its peculiar clinical presentation usually as an effusion and less commonly as a 
tumor mass around a breast implant, and in the light of its peculiar epidemiology and usually indolent 
clinical course55,56.  PTCL-NOS remains a diagnosis of exclusion - notably implying the exclusion of a 
TFH expression - and a heterogeneous category. Two molecular subtypes based on gene expression 
profiles related to Th1 or TH2 subsets of helper T cells, have been defined and can be identified by a 
surrogate immunohistochemistry-based algorithm57,58. A small subset of primary nodal PTCL-NOS are 
associated to EBV infection of the neoplastic cells; these cases differ from extranodal NK/T-cell 
lymphoma, nasal type as they tend to be more monomorphic, usually lack angioinvasion and necrosis, 
and do not express CD5659.   
 
Hodgkin lymphomas and gray zone lymphomas 
Hodgkin lymphomas (HLs)differ from most other lymphomas in their unique cellular composition 
comprising a minority of large atypical neoplastic cells (Hodgkin and Reed-Sternberg (HRS) cells and 
their variants) outnumbered by non-neoplastic reactive cells60. After decades of uncertainties and 
speculations regarding the nature of this malignancy, genetic molecular studies conducted on 
microdissected HRS cells established that HLs are neoplasms of large B cells and represent clonal 
populations of transformed germinal center B cells 61-66. Remarkably, however, the historical distinction 
between Hodgkin’s disease and non-Hodgkin lymphomas survived the successive classifications of 
lymphomas over time - reflecting not only the peculiar morphological range of HL but also its distinctive 
clinical presenting features and distinctive responses to certain chemotherapeutic combinations and 
radiation therapy. 
Classic HLs (cHLs) and nodular lymphocyte predominant HL (NLPHL) represent two 
distinctive groups of diseases (Table 2). In cHL subclassified into four subtypes according to the cellular 
composition of the background infiltrate, the neoplastic Hodgkin and Reed-Sternberg (HRS) which may 
harbor the Epstein-Barr virus (EBV) cells are typically positive for CD30 (an activation marker) and for 
CD15 (an antigen associated with the granulocyte and monocyte lineages), while they usually lack 
expression of CD45 and of molecules characteristic of the B and T-cell lineages67. In contrast, in 
NLPHL, the neoplastic LP “popcorn” cells, have a B-cell immunophenotype 68, and in its classical form 
develop within large follicular structures69. Six distinct histological patterns of NLPHL (A to F) have 
been recognized70and should be described in the diagnosis since the “non-classical” patterns (C to F) 
tend to correlate with higher disease stage and a higher risk of relapse71. There are clinical similarities 
and some morphologic overlap between the lymphocyte-rich subtype of cHL and NLPHL, which 
explains a high rate of misdiagnoses in the past72. However, despite the facts that the neoplastic cells in 
lymphocyte-rich cHL tend to have preserved expression of B-cell markers and develop in a follicular 
microenvironment rich in PD1-positive cells, similar to NLPHL 73the two entities are separated by other 
key distinctive features. 
 The term “gray-zone lymphomas” was coined to denote lymphoproliferations rich in large cells 
and difficult to classify due to morphological or immunophenotypic overlapping features between 
Hodgkin and non-Hodgkin lymphomas, suggesting the possibility of a biological overlap or 
continuum74. Some of the differential diagnoses considered under the “gray-zone” umbrella, in 
particular anaplastic large cell lymphoma versus cHL, have been resolved with the refinement of 
diagnostic criteria and the use of expanded immunohistochemistry and molecular genetic testing. 
Currently, there remains essentially two gray zone areas, one each around cHL and NLPHL.  
The category of B-cell lymphoma, unclassifiable, with features intermediate between diffuse 
large B-cell lymphoma and cHL, which was a provisional entity in the 2008 classification, was promoted 
to a definitive status in 2017. This entity mostly applies mostly to mediastinal cases showing both 
overlapping features between nodular sclerosis HL and primary mediastinal large B-cell lymphoma, and 
significant discordances between morphology and immunophenotype preventing from allocating the 
case to one of each of the well-defined entities75. The patients who are often young males, tend to 
experience a clinical course more aggressive than those with either Hodgkin or large B-cell lymphoma76. 
The notion of a biological continuum is supported by the partial overlap in the molecular and genetic 
features of mediastinal cHL, large B-cell lymphoma and gray-zone cases77-79. Recent studies have 
highlighted considerable variability among pathologists towards the diagnosis of mediastinal gray zone 
lymphomas, and the lack of consensus criteria79,80. EBV-positive cases should be excluded from the 
gray zone category as it turns out that these cases are either syncytial forms of EBV-positive nodular 
sclerosis HL, or  part of the spectrum of EBV-positive diffuse large B-cell lymphomas.    
The relationship and borderline between NLPHL and T-cell/histiocyte-rich large B-cell 
lymphoma has been addressed abundantly in the literature and remains a matter of debate81. The diffuse 
pattern of NLPHL which is often T-cell-rich, closely resembles de novo T-cell/histiocyte-rich large B-
cell lymphoma not only on morphological grounds, but also at the transcriptional and genomic levels, 
with common recurrent mutations in DUSP2, JUNB, SGK1 and SOCS1, and tends to follow a somewhat 
aggressive course82,83. However, it is recommended in the WHO classification to restrict the diagnosis 
of T-cell/histiocyte-rich large B-cell lymphoma to de novo cases, and to employ the term “T-
cell/histiocyte-rich large B-cell lymphoma-like transformation” in cases progressing from NLPHL or 
arising in association with the classical nodular pattern of NLPHL 21. 
 
Lymphomas of the digestive system 
Lymphomas involving the gastrointestinal (GI) tract account for about 30 to 40% of extranodal 
lymphomas 84,85. Most cases correspond to entities that are not specific to the GI tract, and a smaller 
fraction correspond to few specific tumor entities primarily arising in the gastrointestinal tract, including 
duodenal-type follicular lymphoma and intestinal T-cell lymphomas. The latest classification introduced 
significant changes in the intestinal T-cell lymphoma comprises four categories: enteropathy-associated 
T-cell lymphoma (EATL), formerly type I EATL and linked to celiac disease and frequent in Northern 
Europe; monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), formerly type II EATL, not 
associated to celiac disease and relatively more frequent in Asia; intestinal T-cell lymphoma NOS, and 
indolent T-cell lymphoproliferative disorder of the GI tract21.  The two subtypes of EATL previously 
considered as variants of the same disease, have been reclassified as two distinct diseases (Figure 4) due 
to differences in their epidemiology and clinical, features, morphology and phenotype, and genetic 
features as highlighted in recent works56,86,87. Intestinal T-cell lymphoma NOS is a category created to 
comprise the cases of primary intestinal T-cell lymphomas not meeting the criteria for either EATL or 
MEITL. Indolent T-cell lymphoproliferative disorder of the GI tract represent a novel category of clonal 
monomorphic proliferations of small T cells showing a superficial/mucosal distribution in the colon or 
anywhere along the GI tract, usually characterized by an indolent behavior and a chronic relapsing 
course88,89. Recent works have demonstrated an association with recurrent gene fusions or point 
mutations90,91.  All the recent updates of the 2017 lymphoma classification are also included in a specific 
section of the blue book on digestive system tumours dedicated to hematolymphoid malignancies92.  
 
Cutaneous lymphomas 
Primary cutaneous lymphomas represent the second most common form of extranodal lymphomas. 
They comprise a heterogenous group of lymphomas that present in the skin without extracutaneous 
disease at the time of diagnosis. Primary cutaneous T-cell lymphomas represent the vast majority of the 
cases while B-cell lymphomas account for 20-25% primary cutaneous lymphomas.  Several primary 
cutaneous lymphoma entities like mycosis fungoides or lymphomatoid papulosis, have highly 
characteristic clinical and histological features; conversely some lymphomas histologically similar to 
systemic lymphomas like follicular lymphoma or diffuse large B-cell lymphomas, often have a 
completely different clinical behavior and prognosis when occurring primarily in the skin. Because of 
these specificities, primary cutaneous lymphomas have been considered separately from systemic 
lymphomas in different classification systems. The consensus classification of the WHO-EORTC 
(World health Organization -European Organization for Research and Treatment of Cancer) published 
the first time in 2005 and recently revised, serves as the reference for the classification and diagnosis of 
primary cutaneous lymphomas93,94. The approach and principles for disease definition and diagnosis are 
similar to those used for systemic lymphomas, with increased contribution of genetic and molecular 
markers in the last edition, but perhaps more importantly  than for systemic lymphomas, it must be 
stressed that clinical data remain essential for a correct diagnosis. For the most part, the terminology 
and defining criteria of the different primary cutaneous lymphoma entities of the updated WHO-EORTC 
classification were already introduced in the 2017 WHO classification of tumors of haematopoietic 
tissues21. The latest edition of the WHO blue book on skin tumors published in 201895, also incorporates 
the revised WHO-EORTC classification more completely with regards to the distinction of two different 
subtypes of cutaneous marginal zone lymphomas, one class-switched and comprising a small proportion 
of neoplastic B cells that are CXCR3-negative, and the other characterized by large nodules of neoplastic 




Table 1  




 Predominantly disseminated 
 Chronic lymphocytic leukemia/ B-cell small lymphocytic lymphoma 
 Monoclonal B-cell lymphocytosis, 
 B-cell prolymphocytic leukemia     
 Splenic marginal zone B-cell lymphoma    
 Hairy cell leukemia 
 Splenic B-cell lymphoma/leukemia, unclassifiable* 
 Splenic diffuse red pulp small B-cell lymphoma*  
 Hairy cell leukemia-variant*  
 Lymphoplasmacytic lymphoma  
 Waldenström macroglobulinemia 
 Monoclonal gammopathy of unknown significance (MGUS) IgM 
 Mu heavy-chain disease 
 Gamma heavy-chain disease 
 Alpha heavy-chain disease 
 Monoclonal gammopathy of unknown significance (MGUS) IgG/A+ 
 Plasma cell myeloma 
 Solitary plasmacytoma of bone 
 Extraosseous plasmacytoma 
 Monoclonal immunoglobulin deposition disease 
 Primary extranodal or nodal 
 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue 
 Nodal marginal zone B-cell lymphoma  
      Pediatric nodal marginal zone lymphoma*   
 Follicular lymphoma 
      In situ follicular neoplasia 
      Duodenal-type follicular lymphoma  
 Pediatric-type follicular lymphoma 
 Large B-cell lymphoma with IRF4 rearrangement* 
 Primary cutaneous follicle center lymphoma  
 Mantle cell lymphoma 
        In situ mantle cell neoplasia   
 Diffuse large B-cell lymphoma (DLBCL)-NOS 
       Germinal center B-cell type 
      Activated B-cell type 
 T-cell/histiocyte-rich large B-cell lymphoma 
 Primary DLBCL of the central nervous system 
 Primary cutaneous DLBCL, leg-type 
 EBV+ DLBCL-NOS 
 EBV+ muco-cutaneous ulcer 
 DLBCL associated with chronic inflammation 
 Lymphomatoid granulomatosis 
 Mediastinal (thymic) large B-cell lymphoma   
 Intravascular large B-cell lymphoma  
 ALK+ large B-cell lymphoma 
 Plasmablastic lymphoma 
 Primary effusion lymphoma 
 HHV8+ DLBCL-NOS*   
 Burkitt lymphoma 
 Burkitt-like lymphoma with 11q aberration*   
 Lymphomatoid granulomatosis 
 High-grade B-cell lymphoma  with MYC and BCL2 and/or BCL6 gene rearrangements* 
 High-grade B-cell lymphoma NOS* 
 B-cell lymphoma unclassifiable with features intermediate between DLBCL and classic 
Hodgkin lymphoma   
 
T and NK-cell Neoplasms 
 
 Predominantly disseminated 
 T-cell prolymphocytic leukemia   
 T-cell large granular lymphocytic leukemia   
 Aggressive NK-cell leukemia 
 Chronic lymphoproliferative disorder of NK cells* 
 Systemic EBV-positive T-cell lymphoma of childhood* 
 Chronic active EBV infection of T- and NK-cell type, systemic form 
 Adult T-cell lymphoma/leukemia (HTLV-1+)   
 Primary extranodal 
 Extranodal NK/T-cell lymphoma, nasal type 
 Enteropathy-associated T-cell lymphoma 
 Monomorphic epitheliotropic intestinal T-cell lymphoma 
 Indolent T-cell lymphoproliferative disorder of the gastro-intestinal tract* 
 Hepatosplenic T-cell lymphoma 
 Subcutaneous panniculitis-like T-cell lymphoma 
 Breast implant-associated anaplastic large cell lymphoma* 
 Subcutaneous panniculitis-like T-cell lymphoma 
 Primary cutaneous  
 Mycosis fungoides 
 Sezary syndrome 
 Primary cutaneous CD30 + lymphoproliferative disorders 
      Lymphomatoid papulosis 
      Primary cutaneous anaplastic large cell lymphoma 
 Primary cutaneous γδ T-cell lymphoma 
 Provisional CD4+ or CD8+ entities* 
 Hydroa vacciniforme-like lymphoproliferative disorder 
 Severe mosquito bite allergy  
 Predominantly nodal 
 Peripheral T-cell lymphoma, not otherwise specified  
 Angioimmunoblastic T-cell lymphoma 
 Follicular T-cell lymphoma 
 Nodal peripheral T-cell lymphoma with T follicular helper phenotype 
 Anaplastic large cell lymphoma, ALK-positive 
 Anaplastic large cell lymphoma, ALK-negative 
   
Hodgkin lymphomas 
 
 Nodular lymphocyte predominant Hodgkin lymphoma   
 Classic Hodgkin lymphoma    
Nodular sclerosis classic Hodgkin lymphoma     
Mixed cellularity classic Hodgkin lymphoma    
Lymphocyte-rich classic Hodgkin lymphoma    
Lymphocyte-depleted classic Hodgkin lymphoma  
 
Immunodeficiency-associated lymphoproliferative disorders  
Post-transplantation lymphoproliferative disorders (PTLD) 
Non-destructive PTLD  
       plasmacytic hyperplasia 
       infectious mononucleosis PTLD 
       florid follicular hyperplasia PTLD 
Polymorphic PTLD 
Monomorphic PTLD 
Classic Hodgkin Lymphoma PTLD 
Other iatrogenic immunodeficiency-associated lymphoproliferative disorders  
 





Evolution of lymphoma classifications (adapted from 99) 
 
Figure 2 
Histogenetic and pathogenetic model of mature B-cell neoplasms 
The follicular (T-cell dependent) and extrafollicular pathways of normal B-cell differentiation are 
represented.  Rearrangement of the IG heavy chain gene is symbolized with a horizontal bar in the 
nucleus, and somatic mutations in the IGV region are symbolized with vertical lines. The most common 
types of mature B-cell neoplasms are linked to their putative normal counterpart. The genetic lesion 
most frequently associated with each lymphoma category is also indicated. 
 
Figure 3 
Overview of the main peripheral T-cell lymphoma entities presenting as nodal diseases 
The three groups of nodal lymphomas depicted on the scheme account for the majority of cases 
presenting with nodal involvement. The category of peripheral T-cell lymphoma not otherwise specified 
(PTCL-NOS) is a diagnosis of exclusion, especially after having discarded the possibility of a TFH 
lymphoma (expressing at least two TFH markers), and after having excluded the possibility of nodal 
involvement by a disseminated T-cell neoplasm (T-cell prolymphocytic leukemia, adult T-cell 
leukemia/lymphoma) or an extranodal or cutaneous lymphoma. PTCL-NOS is a heterogenous category 
comprising several subsets defined by gene expression signatures resembling those of T Helper 1 or 2 
cells (T-BET and GATA-3, respectively), EBV-positive tumors and neoplasms with a cytotoxic 
phenotype. 
AITL: angioimmunoblastic T-cell lymphoma; ALCL: anaplastic large cell lymphoma; ALK: anaplastic 




Evolution of the categorization of intestinal T-cell lymphomas 
Primary intestinal T-cell lymphomas were collectively considered in the 2008 classification as one 
disease entity, enteropathy-associated T-cell lymphoma, of which two variants, type I (classical), and 
type II were recognized. In the 2017 classification, these two variants are considered as separate 
diseases, and designated enteropathy-associated T-cell lymphoma (EATL) (former type I) and 
monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) (former type II).  EATL is typically 
pleomorphic, often associated with an inflammatory component and necrosis. MEITL as its name 
implies, is composed of a monomophic lymphoid cell proliferation and infiltrates the adjacent 
epithelium of intestinal villi and crypts. In addition to EATL and MEITL, the current classification also 
recognizes a subset of cases not fulfilling the criteria for either EATL or MEITL, designated “intestinal 
T-cell lymphoma, not otherwise specified” as well as a category of indolent clonal T-cell 
lymphoproliferative disorders. Moreover, other lymphoma types may present with intestinal 
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Classic Hodgkin Lymphoma (cHL)
> 90% of HL














Four types: Nodular Sclerosis and Mixed Cellularity most
common; Lymphocyte-rich, or Lymphocyte–depleted less
common
Six patterns: classical B-cell rich nodular (A), 
serpiginous/interconnexted (B); with promiennt extranodular LP 
cells (C); T-cell rich nodular (D); diffuse (T-cell/histiocyte-rich large 
B-cell lymphoma like) (E); diffuse B-cell-rich (F).
IG: clonal, mutated, crippled mutations
Mutations in STAT6, SOCS1; PDL1/PDL2 alterations, CIITA
rearrangements
IG: clonal, mutated
BCL6 rearrangements, mutations in DUSP2, JUN, SGK1, SOCS1
Gray zone: unclassifiable B-cell lymphoma with features
intermediate between diffuse large B-cell lymphoma and cHL
Gray zone: diffuse NLPHL versus T-cell/histiocyte-rich large B-cell
lymphoma
Table 2
Summary of distinguishing featrures of classic and nodular lymphocyte predomionant Hodgkin lymphomas
Table
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